Fjarde Ap Fonden Bei Gene, Ltd. Transaction History

Fjarde Ap Fonden

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $1.24 Million - $1.77 Million	-5,600 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$123.9 - $195.41 $99,120 - $156,328	800 Added 16.67%	5,600 $1.06 Million
Q4 2019 Feb 10, 2020	BUY	$115.78 - $208.34 $69,468 - $125,004	600 Added 14.29%	4,800 $796,000
Q3 2019 Oct 31, 2019	BUY	$120.61 - $148.29 $36,183 - $44,487	300 Added 7.69%	4,200 $514,000
Q1 2019 Apr 29, 2019	BUY	$122.82 - $151.83 $36,846 - $45,549	300 Added 8.33%	3,900 $515,000
Q4 2018 Jan 31, 2019	BUY	$107.01 - $175.15 $385,236 - $630,540	3,600 New	3,600 $505,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.